Ed and Ethel Moore Alzheimer's Disease Research Grant Program

The Florida Department of Health administers the Alzheimer's Disease Research Grant Advisory Board Grant Program, identified within the funding announcement as the Ed and Ethel Moore Alzheimer's Disease Research Grant Program. The Alzheimer's Disease Research Grant Advisory Board was created within the Department under section 381.82, Florida Statutes, and advises the State Surgeon General regarding the scope and priorities of Alzheimer's disease research grants. The program supports high-priority research intended to advance the prevention, diagnosis, treatment, care management, and potential cure of Alzheimer's disease, with an emphasis on benefits to the people of Florida. Research may range from pilot investigations to mature projects advancing therapeutic approaches or concepts. Applications must address one of five research priority areas. These include behavioral and social needs of persons with Alzheimer's disease and their caregivers; therapeutic targets, therapeutic strategies, disease mechanisms, genetic factors, co-morbidities, and biomarkers; collaborative clinical research through consortia of Florida institutions; epidemiologic research addressing neurodegenerative, cardiac, vascular, genetic, and epigenetic contributors to cognitive impairment; and clinical, patient-oriented postdoctoral research fellowship training. The FOA provides four grant categories: Consortium, Standard, Pilot, and Postdoctoral Research Fellowship grants. Consortium grants may receive up to $750,000 and Standard grants up to $350,000, each for a maximum of 48 months. Pilot and Postdoctoral Research Fellowship grants may receive up to $100,000, each for a maximum of 24 months. Continued grant duration is contingent on legislative spending authority from fiscal year to fiscal year. Allowable project costs include salaries and fringe benefits, supplies, qualifying equipment, laboratory services, consultant costs, patient and animal care, applicable research committee fees, consortium or contractual costs, certain Department data fees, domestic travel, tuition when appropriately documented, background screening when required, and research participant incentives subject to applicable approvals. Consultant costs may not exceed 10 percent of the total budget, and indirect costs may not exceed 15 percent of total direct costs requested. Disallowed expenses include Florida Department of Health personnel salaries, construction or renovation, international travel, vehicles, entertainment, employment subsidies, dues or membership fees, lobbying, meals except allowable travel-related costs, malpractice insurance premiums, and specified immigration or legal processing expenses. The FOA does not state a required cost share or matching contribution. Eligible applicants include Florida-based universities and established research institutes, with the FOA's definitions also identifying Florida universities or research hospitals, Florida-based Veterans Administration hospitals, and qualifying established research institutes in Florida as eligible institutions. An established research institute is defined as a Florida-based nonprofit organization legally registered with the Florida Department of State, maintaining a physical Florida location, and having a stated scientific, biomedical, or biotechnological research or development purpose. All grant-funded activities, effort, and expenditures must generally occur in Florida. Limited exceptions may be approved for essential services available only outside Florida when the amount is less than 10 percent of the total award. Each application must name one Corresponding Principal Investigator who is employed by the applicant organization, meets the organization's PI requirements, and is a U.S. citizen or permanent resident. Scientific, financial, and effort overlap with other projects is prohibited. Applications are submitted through the online application system accessed from the Department's Biomedical Research Program Funding Opportunity Announcements web page. Applicants must register, complete the project profile and online application, and submit all required sections and attachments in the required formats before the deadline. Required components include General Project Information, a General Audience Abstract, Scientific Abstract, Health Impact narrative, Alzheimer's-Relatedness explanation, Collaborator Information, biographical sketches, Specific Aims, the Budget Template with budget summary and narrative, and a Work Plan identifying milestones for the entire project period. Human-subject, vertebrate-animal, recombinant-DNA, survey-instrument, and consultant materials are required when applicable. Letters of support may be submitted where applicable, and images, graphs, or figures may be uploaded separately. Application documents must generally be in PDF format and conform to the specified font, margin, page-size, line-spacing, and file-size requirements. Eligible applications first undergo administrative review for timeliness, completeness, mandatory eligibility requirements, and potential scientific or budgetary overlap. Qualified applications proceed to peer review by experts outside Florida. Peer reviewers assess overall impact based on significance, investigators, innovation, approach, environment, and health impact on Floridians. Applications scoring within the top 30 percent during individual review proceed to the peer-review panel stage. The Department and the Board then conduct programmatic review, considering peer-review scores, available funds, program goals, and program preferences before recommendations are made to the State Surgeon General. Funding decisions are final. Awardees must accept non-negotiable Terms and Conditions and comply with reporting, open-access, progress-reporting, and financial-reporting requirements. For this competition, the application was anticipated to open November 3, 2025, with emailed questions due by 5:00 p.m. ET on November 5, 2025 and applications due by 12:00 p.m. ET on November 18, 2025. The cover page states an award period of July 1, 2025 through June 30, 2026, while individual grant categories may have maximum durations of 24 or 48 months subject to annual legislative spending authority. A later budget-instructions section separately states an anticipated April 1, 2025 grant start date, which is inconsistent with the cover-page award period and the November 2025 application deadline; the FOA itself does not reconcile this discrepancy. Programmatic questions are directed to research@flhealth.gov, the general office phone is 850-245-4585, and online application help is available at Help.FLDOH@orau.org. The FOA does not expressly state that this solicitation recurs annually or on another fixed schedule.

Select the correct grant category and Priority Area because an incorrect Priority Area makes an application ineligible for peer review or funding. Clearly demonstrate significance, investigator qualifications, innovation, approach, environment, and health impact on Floridians. Align the research with one of the five stated priority areas and provide a complete milestone-based Work Plan. Avoid scientific, financial, or effort overlap with other projects. Follow all PDF, font, margin, file-size, signature, and attachment requirements and submit early because late applications are not considered. Consortium applicants should establish well-defined institutional roles, substantive lead-institution oversight, and a scientifically rigorous collaboration.